Related Experiment Video
Updated: May 2, 2026
Stereotactic Radiosurgery for Gynecologic Cancer
Published on: April 17, 2012
Safety and Efficacy of Hypofractionated Preoperative Radiation Therapy in Retroperitoneal Sarcoma: A Comparative
Jong Yun Baek1, Jeong Il Yu1, Kyo Won Lee2
1Departments of Radiation Oncology, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Republic of Korea.
Purpose:
The role of preoperative radiation therapy (RT) in retroperitoneal sarcoma (RPS) remains controversial across histologic subtypes. Conventional fractionated RT (ConvRT) is the current standard, but hypofractionated RT (HypoRT) is gaining interest, particularly for soft-tissue sarcomas. This study aimed to compare the safety and efficacy of HypoRT (10 fractions) with ConvRT in patients with RPS.
Methods And Materials:
We retrospectively reviewed 55 patients with RPS who received preoperative RT followed by surgery at a single tertiary institution between 2017 and 2024. All patients underwent intensity modulated RT with simultaneous integrated boost techniques. The HypoRT group (n = 15) received 50/35 Gy in 10 fractions, and the ConvRT group (n = 40) received 62.5/45 Gy in 25 fractions. We assessed surgical complications (Clavien-Dindo grade ≥3) and prolonged postoperative hospitalization (≥14 days).
Results:
Baseline characteristics were comparable. HypoRT did not increase grade ≥3 complications (33.3% vs 25.0%, P = .735) or hospital stay (median, 16 vs 13 days; P = .684). Older age was associated with severe complications (P = .027), whereas larger tumors and longer operation time correlated with extended hospitalization (P = .018 and P = .024, respectively). With a median follow-up of 33 months, 3-year local recurrence-free survival (71.5% vs 48.9%, P = .329), progression-free survival (59.3% vs 44.4%, P = .612), and overall survival (84.9% vs 80.0%, P = .578) were comparable between groups.
Conclusions:
HypoRT in 10 fractions appears feasible, without an apparent increase in perioperative morbidity and may offer a potential alternative to ConvRT in patients with resectable RPS.
